Sveriges mest populära poddar

Recent Licensing Agreement Poised to Advance Company ADC

23 min•26 januari 2024

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.

Fler avsnitt av Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves Datroway

22 maj•2 min

Pharmaceutical Executive Daily: What It Takes to Move Machine Learning

21 maj•3 min

Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio

20 maj•4 min

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

19 maj•3 min

Rethinking Pharma's Go-to-Market Formula

19 maj•21 min

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

18 maj•2 min

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

15 maj•3 min

Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi

14 maj•4 min

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

13 maj•3 min

Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen

11 maj•3 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.